Cellular Origins appoints Peter Crossley as chief operating officer
January 25, 2024Business Services Cellular Origins, Peter Crossley, appointment, chief operating officer
Cellular Origins, a TTP Company, has announced that it has appointed Peter Crossley as chief operating officer (COO). Peter brings …
BenevolentAI appoints Dr Joerg Moeller as CEO
January 25, 2024Business Services BenevolentAI, CEO, Dr Joerg Moeller, appointment
BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member …
Onward Therapeutics announces enrolment of phase 1 trial of bispecific antibody
January 24, 2024Research and Development Oncology, Onward Therapeutics, bispecific antibody, clinical trial
Onward Therapeutics has announced that it has begun enrolment for its phase 1 clinical trial of OT-A201, a novel bispecific …
InnoCare announces first patient dosed in zurletrectinib clinical trial in China
January 24, 2024Research and Development InnoCare, Oncology, clinical trial, zurletrectinib
InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second …
CN Bio and Altis Biosystems partner for development of in vitro model for ADME studies
January 23, 2024Research and Development ADME studies, Altis Biosystems, CN Bio, Pharmacy
CN Bio and Altis Biosystems have announced that they will enter a strategic partnership, through which Altis’ human RepliGut Planar-Jejunum …
Sanofi to acquire Inhibrx for approximately $1.7bn
January 23, 2024Business Services Inhibrx, Rare Diseases, Sanofi, acquisition
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …
UKHSA warns of measles outbreak
January 22, 2024Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination
The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …
FDA approves Balversa for bladder cancer treatment
January 22, 2024Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer
Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
AstraZeneca’s Voydeya approved in Japan for PNH treatment
January 19, 2024Medical Communications AstraZeneca, Haematology, PNH, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …
Verastem Oncology gains Fast Track Designation for combination NSCLC treatment
January 19, 2024Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology
Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …
FDA clears DermaSensor’s AI detection device for skin cancer
January 18, 2024Medical Communications FDA, Oncology, skin cancer
DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …
Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment
January 18, 2024Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial
Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …
FDA clears Aruna Bio’s IND for AB126 to enter clinical trials
January 17, 2024Research and Development Aruna Bio, FDA, IND, Neurology, clinical trials
Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
January 17, 2024Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …
Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing
January 16, 2024Manufacturing and Production Pharmacy, Upperton Pharma Solutions, investment, sterile drug manufacturing
UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment to expand into a small-scale …
DelSiTech announces closing of €10m financing round for silica-based drug delivery platform
January 16, 2024Manufacturing and Production DelSiTech, Pharmacy, drug delivery, investment, manufacturing
DelSiTech has announced the successful completion of a €10m financing round, marking the largest single financing round in the company’s …
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
January 15, 2024Medical Communications FDA, Oncology, cervical cancer, keytruda
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Boan Biotech completes enrolment for phase 3 study of Denosumab
January 15, 2024Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab
Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
January 12, 2024Medical Communications COVID-19, Infections and infestations, NICE
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
